Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation

Leukemia. 2020 Feb;34(2):651-655. doi: 10.1038/s41375-019-0565-y. Epub 2019 Aug 29.

Authors

Nicolas G Kint^{1

2}, Elien Heylen^{3

4

5}, Daniele Pepe⁵, Kim De Keersmaecker⁵, Catherine M Verfaillie⁴, Michel Delforge^{3

4}

Affiliations

¹ Department of Internal Medicine-Hematology, University Hospitals Leuven, Leuven, Belgium. nicolas.kint@uzleuven.be.
² Stem Cell Institute Leuven, KU Leuven, Leuven, Belgium. nicolas.kint@uzleuven.be.
³ Department of Internal Medicine-Hematology, University Hospitals Leuven, Leuven, Belgium.
⁴ Stem Cell Institute Leuven, KU Leuven, Leuven, Belgium.
⁵ Laboratory for Disease Mechanisms in Cancer, KU Leuven, Leuven, Belgium.

PMID: 31467428
DOI: 10.1038/s41375-019-0565-y

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

3T3 Cells
Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Erythroid Cells / drug effects
Female
Humans
Male
Mice
Middle Aged
Multiple Myeloma / drug therapy*
Oligopeptides / therapeutic use*
Proteasome Inhibitors / therapeutic use*
Reticulocytosis / drug effects*
Retrospective Studies

Substances

Oligopeptides
Proteasome Inhibitors
carfilzomib